EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY-NC 4.0

Real‐World Effectiveness and Safety of Recombinant Human Follicle‐Stimulating Hormone (rhFSH) in Infertile Women undergoing Assisted Reproductive Technology (ART): A Korean Nationwide Cohort Study

Joong Yeup Lee iD, Eun-Young Choi iD, Jung Ryeol Lee iD, Young Sik Choi iD, Ji Hyang Kim iD, Chang-Woo Choo iD, Yunju Choe iD, Hee-Jin Seo iD, Hyesung Lee iD, Yujeong Shin iD, Yejin Jeon iD, Ju-Young Shin iD und 1 weitere

Clinical Pharmacology & Therapeutics · 2026-02 · 119 (2) · 514-523

DOI: 10.1002/cpt.70136 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Clinical Pharmacology & Therapeutics, online erschienen am 02.12.2025. Verfasst von Joong Yeup Lee und 12 weiteren Autor:innen. Beteiligte Einrichtung: Hamchoon Women's Clinic, Seoul, South Korea. Hauptthemen laut MEDLINE: Infertility, Female, Follicle Stimulating Hormone, Human, Reproductive Techniques, Assisted. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Life Sciences, LG Chem, Ltd., Life Sciences, University of California, Los Angeles.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Despite widespread rhFSH use in infertile women undergoing ART, real‐world comparative data on its effectiveness and safety across different rhFSH types remain limited. Using the HIRA claims database, we included 10,684 women aged 20–39 with infertility (2016–2021) who used only rhFSH in their first in vitro fertilization–embryo transfer (IVF‐ET). Outcome variables comprised effectiveness (≥ 11 oocytes retrieved, pregnancy rates and live birth rate) and safety (ectopic pregnancy, miscarriage, preterm birth and ovarian hyperstimulation syndrome [OHSS]) in the whole cohort, further categorized into follitropin and other rhFSH. Baseline characteristics were described, and relative risks (RR) with 95% confidence intervals (CI) were estimated using a generalized linear model, adjusting for age and imbalanced variables. Of 10,684 patients prescribed rhFSH, 7.1% were aged 20–29, 41.6% were 30–34, and 51.3% were 35–39. ICSI was utilized in 57.7% of cycles, and 76.8% used the GnRH antagonist protocol. The live birth rate was 38.8%, and the OHSS rate was 5.9%. Comparing baseline characteristics of the follitropin ( n = 2,594) and other rhFSH group ( n = 8,090), ICSI (62.2% vs. 56.3%) and GnRH antagonist protocol (81.3% vs. 75.3%) were more common in the follitropin group. Women who received follitropin were more likely to have ≥ 11 oocytes retrieved (adjusted RR, 1.09; 95% CI: 1.02–1.16) and less likely to have OHSS (adjusted RR, 0.73; 95% CI: 0.60–0.90). These findings provide real‐world evidence supporting rhFSH effectiveness and safety in fresh IVF cycles, with follitropin potentially offering advantages in oocyte retrieval and reduced OHSS rates.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Infertility, FemaleFollicle Stimulating Hormone, HumanReproductive Techniques, AssistedHumansFemaleAdultPregnancyPregnancy RateRepublic of KoreaRecombinant ProteinsYoung AdultCohort StudiesFertilization in VitroLive BirthTreatment OutcomeOvarian Hyperstimulation SyndromeOocyte Retrieval

Substanzen

Follicle Stimulating Hormone, HumanRecombinant Proteins

Autor:innen und Institutionen

  • Hamchoon Women's Clinic, Seoul, South Korea.
  • School of Pharmacy, Sungkyunkwan University, Suwon, South Korea.
  • Clinical Epidemiology Division, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden.
  • Department of Obstetrics and Gynecology, Seoul National University Bundang Hospital, Seongnam, South Korea.
  • Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, South Korea.
  • Institute of Women's Life Medical Science, Yonsei University College of Medicine, Seoul, South Korea.

ORCID-Profile: Joong Yeup Lee, Eun-Young Choi, Jung Ryeol Lee, Young Sik Choi, Ji Hyang Kim, Chang-Woo Choo, Yunju Choe, Hee-Jin Seo, Hyesung Lee, Yujeong Shin, Yejin Jeon, Ju-Young Shin, Hoon Kim

Förderung

  • Life Sciences, LG Chem, Ltd.
  • Life Sciences, University of California, Los Angeles

Zitieren

APA

Lee, J. Y., Choi, E. Y., Lee, J. R., Choi, Y. S., Kim, J. H., Choo, C. W., Choe, Y., Seo, H. J., Lee, H., Shin, Y., Jeon, Y., Shin, J. Y., & Kim, H. (2026). Real‐World Effectiveness and Safety of Recombinant Human Follicle‐Stimulating Hormone (rhFSH) in Infertile Women undergoing Assisted Reproductive Technology (ART): A Korean Nationwide Cohort Study. Clinical Pharmacology & Therapeutics, 119(2), 514-523. https://doi.org/10.1002/cpt.70136

Vancouver

Lee JY, Choi EY, Lee JR, Choi YS, Kim JH, Choo CW, et al. Real‐World Effectiveness and Safety of Recombinant Human Follicle‐Stimulating Hormone (rhFSH) in Infertile Women undergoing Assisted Reproductive Technology (ART): A Korean Nationwide Cohort Study. Clinical Pharmacology & Therapeutics. 2026;119(2):514-523. doi:10.1002/cpt.70136

BibTeX
@article{Lee2026,
  author = {Lee, Joong Yeup and Choi, Eun-Young and Lee, Jung Ryeol and Choi, Young Sik and Kim, Ji Hyang and Choo, Chang-Woo and Choe, Yunju and Seo, Hee-Jin and Lee, Hyesung and Shin, Yujeong and Jeon, Yejin and Shin, Ju-Young and Kim, Hoon},
  title = {Real‐World Effectiveness and Safety of Recombinant Human Follicle‐Stimulating Hormone (rhFSH) in Infertile Women undergoing Assisted Reproductive Technology (ART): A Korean Nationwide Cohort Study},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2026},
  volume = {119},
  number = {2},
  pages = {514--523},
  doi = {10.1002/cpt.70136}
}
Kostenlos starten →